Mayo Clinic Collaborates With PN Medical on a Research Study of Long COVID Patients

The clinical trial aims to identify solutions to combat the respiratory symptoms of post-acute COVID syndrome

PN Medical, a leading developer of cardiopulmonary training devices, is supporting Mayo Clinic in a clinical trial to identify new approaches to treat the symptoms of post-acute COVID syndrome (PACS). The COVID Virtual Recovery Study will focus on people who have tested positive for the SARS-CoV2 infection and have completed a 14-30 day quarantine.

A new study from the University of Oxford reports that more than one-third of COVID-19 patients may experience lingering symptoms for months following infection.1 Commonly referred to as Long COVID, some of the more common symptoms of post-acute COVID syndrome (PACS) include shortness of breath, fatigue, brain fog, loss of taste and smell, joint pain and depression. Health experts say the condition is clearly of public health concern, given the substantial impact it has on society, ranging from increased health care costs to economic and productivity losses.2

The goal of Mayo Clinic’s COVID Virtual Recovery Study is to investigate the benefits of respiratory muscle training (RMT) on strengthening the respiratory system and accelerating recovery from COVID-19. The findings will focus on functional recovery, mental wellbeing, and the ability to return to work or to pre-COVID daily activities.

“The respiratory system is central to a number of the lingering symptoms of long COVID,” explained Mark A. Carbone, CEO of PN Medical. “Implementing respiratory muscle training can positively impact the pathways involved in breathing and provide a gradual, progressive method to improve respiratory muscle function.”

The four-week study is completely virtual, allowing anyone in the U.S. who has been affected by COVID-19 to apply. Participants will receive PN Medical’s respiratory muscle training device (THE BREATHER or BREATHER FIT) and follow a training plan on the BREATHER COACH connected app that requires using the device up to two times a day on a specific number of days per week to test its effectiveness in reducing long COVID symptoms.

Interested persons can determine their eligibility and enroll in the COVID Virtual Recovery Study by visiting https://www.pnmedical.com/covid-virtual-recovery-study-cvrs-2/.

“PN Medical shares Mayo Clinic’s dedication to evidence-based science and cutting-edge research; in this case to develop drug-free solutions to help people improve their respiratory health,” said Carbone. “My hope is that this research study with Mayo Clinic will result in new protocols that lead to COVID resilience before, during and after positive exposure to the virus.”


References

  1. Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom
  2. Long COVID now has a formal definition. Here’s what you need to know

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”